| What is the conservation value of a plant in a botanic garden? Using indicators to improve management of ex situ collections A Cibrian-Jaramillo, A Hird, N Oleas, H Ma, AW Meerow, ... The Botanical Review 79, 559-577, 2013 | 97 | 2013 |
| T-cell lymphomas, a challenging disease: types, treatments, and future H Ma, M Abdul-Hay International journal of clinical oncology 22, 18-51, 2017 | 37 | 2017 |
| Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ... Cancer 126 (2), 293-303, 2020 | 32 | 2020 |
| A web-based multimedia program before colonoscopy increased knowledge and decreased anxiety, sedation requirement, and procedure time S Parker, J Zipursky, H Ma, GL Baumblatt, CA Siegel Journal of clinical gastroenterology 52 (6), 519-523, 2018 | 31 | 2018 |
| Survival benefit in patients with peripheral T‐cell lymphomas after treatments with novel therapies and clinical trials H Ma, B Cheng, L Falchi, E Marchi, A Sawas, G Bhagat, OA O'Connor Hematological Oncology 38 (1), 51-58, 2020 | 26 | 2020 |
| The future of combination therapies for peripheral T cell lymphoma (PTCL) H Ma, A Davarifar, JE Amengual Current hematologic malignancy reports 13, 13-24, 2018 | 25 | 2018 |
| The peripheral T-cell lymphomas: an unusual path to cure H Ma, E Marchi, OA O'Connor The Lancet Haematology 7 (10), e765-e771, 2020 | 19 | 2020 |
| Potentially inappropriate medication use in elderly non‐Hodgkin lymphoma patients is associated with reduced survival and increased toxicities RJ Lin, H Ma, R Guo, AB Troxel, CS Diefenbach British journal of haematology 180 (2), 267-270, 2018 | 15 | 2018 |
| New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination H Ma, OA O’Connor, E Marchi Expert Review of Hematology 12 (3), 137-146, 2019 | 13 | 2019 |
| Combining biology and chemistry for a new take on chemotherapy: antibody-drug conjugates in hematologic malignancies H Ma, A Sawas Current Hematologic Malignancy Reports 13, 555-569, 2018 | 6 | 2018 |
| Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma A Sawas, H Ma, A Shustov, P Hsu, G Bhat, M Acosta, S Horwitz, ... Leukemia & lymphoma 61 (8), 2003-2007, 2020 | 5 | 2020 |
| The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). E Marchi, H Ma, F Montanari, A Sawas, JK Lue, C Deng, KT Whitfield, ... Journal of Clinical Oncology 38 (15_suppl), 8049-8049, 2020 | 5 | 2020 |
| Belinostat induces high overall response rate (ORR) in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) A Sawas, H Ma, A Shustov, P Hsu, G Bhat, M Acosta, SM Horwitz, ... Blood 134, 4050, 2019 | 5 | 2019 |
| Randomized Controlled Trial Demonstrates a Web-based Multimedia Program Used Prior to First-Time Colonoscopy Decreased Patient Anxiety, Sedation Requirement, and Procedure Time … S Parker, J Zipursky, H Ma, C Siegel Official journal of the American College of Gastroenterology| ACG 108, S645, 2013 | 4 | 2013 |
| Polypharmacy and potentially inappropriate medication use in older patients with aggressive non-Hodgkin lymphoma (NHL) leads to inferior survival and increased treatment … RJ Lin, H Ma, R Guo, ML Grossbard, AB Troxel, CS Magid Diefenbach Journal of Clinical Oncology 35 (15_suppl), 10039-10039, 2017 | 3 | 2017 |
| Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory … A Sawas, H Ma, J Kuruvilla, JK Lue, C Deng, E Marchi, F Montanari, ... Leukemia & Lymphoma 61 (12), 3014-3017, 2020 | 2 | 2020 |
| Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series H Ma, B Cheng, F Montanari, JK Lue, C Deng, E Marchi, OA O’Connor, ... Therapeutic Advances in Hematology 11, 2040620720947340, 2020 | 2 | 2020 |
| Abstract CT160: The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma E Marchi, H Ma, F Montanari, A Sawas, JK Lue, C Deng, KT Whitfield, ... Cancer Research 80 (16_Supplement), CT160-CT160, 2020 | 2 | 2020 |
| A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature H Ma, G Bhagat, OA O'Connor Leukemia & Lymphoma, 2019 | 2 | 2019 |
| Survival outcomes of patients with peripheral T-cell lymphomas (PTCL) treated with chemotherapy and/or novel agents: The Columbia University experience. H Ma, B Cheng, OA O'Connor Journal of Clinical Oncology 37 (15_suppl), e19049-e19049, 2019 | 2 | 2019 |
